Mouse models for gastric cancer: Matching models to biological questions

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 7, 2016, Pages 1257-1272

  Poh, Ashleigh R ^a,b   O'Donoghue, Robert J J ^c   Ernst, Matthias ^c   Putoczki, Tracy L ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

Author keywords

diffuse gastric cancer; Helicobacter pylori; intestinal type gastric cancer; mouse model

Indexed keywords

CARBONATE DEHYDRATASE; GASTRIN; GLYCOPROTEIN GP 130; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; N [1 (1,3 BENZODIOXOL 5 YL)BUTYL] 3,3 DIETHYL 2 [4 [(4 METHYL 1 PIPERAZINYL)CARBONYL]PHENOXY] 4 OXO 1 AZETIDINECARBOXAMIDE; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR CDX2; TREFOIL PEPTIDE; VASCULOTROPIN; METHYLNITROSOUREA;

CANCER PROGNOSIS; DISEASE COURSE; GENETIC MODEL; HELICOBACTER FELIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MOUSE; MOUSE MODEL; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS; ANIMAL; CLASSIFICATION; DISEASE MODEL; GENETICS; INBRED MOUSE STRAIN; MOLECULARLY TARGETED THERAPY; STOMACH NEOPLASMS; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; GASTRINS; HELICOBACTER FELIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METHYLNITROSOUREA; MICE, INBRED STRAINS; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; STOMACH NEOPLASMS;

EID: 84979608843     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13297     Document Type: Review

References (186)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin D. Estimates of worldwide burden of cancer in 2008. Int. J. Cancer 2010; 127: 2893–917.
2. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009; 374: 477–90.
3. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69–90.
4. Yuasa Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat. Rev. Cancer 2003; 3: 592–600.
5. TCGA. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202–9.
6. Cristescu R, Lee J, Nebozhyn M et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 2015; 21: 449–56.
7. Fox J, Wang T. Inflammation, atrophy and gastric cancer. J. Clin. Invest. 2007; 117: 60–9.
8. Li Q, Karam S, Gordon J. Diphtheria toxin-mediated ablation of parietal cells in the stomach of transgenic mice. J. Biol. Chem. 1996; 271: 3671–6.
9. Zavros Y, Eaton K, Kang W et al. Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma. Oncogene 2005; 24: 2354–66.
10. Cai X, Carlson J, Stoicov C, Li H, Wang T, Houghton J. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in CD57BL.6 mice. Gastroenterology 2005; 128: 1937–52.
11. Goldenring J, Nomura S. Differentiation of the gastric mucosa III. Animals models of oxyntic atrophy and metaplasia. Am. J. Physiol. Gastrointest. Liver Physiol. 2006; 291: G999–G1004.
12. Hattori T. Development of adenocarcinomas in the stomach. Cancer 1896; 57: 1528–34.
13. Schmidt P, Lee J, Joshi V et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab. Invest. 1999; 79: 639–46.
14. Halldorsdottir A, Sigurdardottrir M, Jonasson J et al. Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. Dig. Dis. Sci. 2003; 48: 431–41.
15. Carl-McGrath S, Ebert M, Rocken C. Gastric adenocarcinoma: epidemiology, pathology and pathogenesis. J. Cancer Ther. 2007; 5: 877–94.
16. Busuttil RA, Zapparoli GV, Haupt S et al. Role of p53 in the progression of gastric cancer. Oncotarget. 2014; 5: 12016–26.
17. Park W, Oh R, Park J et al. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res. 1999; 59: 4257–60.
18. Mattioli E, Vogiatzi P, Sun A et al. Immunohistochemical analysis of pRb2/p130, VEGF, EH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J. Cell. Physiol. 2007; 210: 183–91.
19. Li X, Yue Z, Zhang Y et al. Elevated serum level and gene polymorphisms of TGF-beta1 in gastric cancer. J. Clin. Lab. Anal. 2008; 22: 164–71.
20. Stock M, Otto F. Gene deregulation in gastric cancer. Gene 2005; 360: 1–19.
21. Barber M, Murrell A, Ito Y, Maia A, Hyland S, Oliveira C. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J. Pathol. 2008; 216: 295–306.
22. Potten C, Darzynkiewicz Z, Sasaki K, Buono RD, Pignatelli M. The role of the E-cadherin complex in gastrointestinal cell differentiation. Cell Prolif. 2003; 32: 79–84.
23. Handschuh G, Candidus S, Luber B et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 1999; 18: 4301–12.
24. Mayer B, Johnson JP, Leitl F et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 1993; 53: 1690–5.
25. Zheng H, Takahashi H, Murai Y et al. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J. Clin. Pathol. 2007; 60: 273–7.
26. Yamachika T, Nakanishi H, Inada K et al. N-Methyl-N-nitrosourea concentration-dependent, rather than total intake-dependent, induction of adenocarcinomas in the glandular stomach of BALB/c mice. Jpn. J. Cancer Res. 1998; 89: 385–91.
27. Yamamoto M, Furihata C, Ogiu T et al. Independent variation in susceptibilities of six different mouse strains to induction of pepsinogen-altered pyloric glands and gastric tumor intestinalization by N-methyl-N-nitrosourea. Cancer Lett. 2002; 179: 121–32.
28. Leung W, Wu K, Wong C et al. Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. Carcinogenesis 2008; 29: 1648–54.
29. Yamamoto M, Tsukamoto T, Sakai H et al. p53 knockout mice (−/−) are more susceptible than (+/−) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis 2000; 21: 1891–7.
30. Sakamoto K, Hikiba Y, Nakagawa H et al. Inhibitor of kappaB kinase beta regulates gastric carcinogenesis via interleukin-1alpha expression. Gastroenterology 2010; 139: 226–38.
31. Shibata W, Maeda S, Hikiba Y et al. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res. 2008; 68: 5031–9.
32. Takasu S, Tsukamoto T, Cao X et al. Roles of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression and beta-catenin activation in gastric carcinogensis in N-methyl-N-nitrosourea-treated K19-C2mE transgenic mice. Cancer Sci. 2008; 99: 2356–64.
33. Ito K, CHuang L, Ito T, Chang T, Fukamachi H, Salto-Tellez M. Loss of Runx3 is a key event in inducing precancerous state of the stomach. Gastroenterology 2011; 140: 1536–46.
34. Humar B, Blair V, Charlton A, More H, Martin I, Guilford P. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res. 2009; 69: 2010–56.
35. Li Q, Jia Z, Wang L et al. Disruption of Klf4 in villin-positive gastric progenitor cells promotes formation and progression of tumors in the antrum of mice. Gastroenterology 2012; 142: 531–42.
36. Boffa L, Bolognesi C. Methylating agents: their target amino acids in nuclear proteins. Carcinogenesis 1985; 6: 1399–401.
37. Tomita H, Takaishi S, Menheniott T et al. Inhibition of gastric carcinogenesis by the hormone gastrin is mediated by suppression of TFF1 epigenetic silencing. Gastroenterology 2011; 140: 879–91.
38. Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014; 345: 196–202.
39. Herrera V, Parsonnet J. Helicobacter pylori and gastric adenocarcinoma. Clin. Microbiol. Infect. 2009; 15: 971–6.
40. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784–9.
41. Polk D, Peek R. Helicobacter pylori: gastric cancer and beyond. Nat. Rev. Cancer 2010; 10: 403–14.
42. Azuma T. Helicobacter pylori CagA protein variation associated with gastric cancer in Asia. J. Gastroenterol. 2004; 39: 97–103.
43. Yuzhalin A. The role of interleukin DNA polymorphisms in gastric cancer. Hum. Immunol. 2011; 72: 1128–36.
44. Hamajima N, Naito N, Kondo T, Goto Y. Genetic factors involved in the development of Helicobacter pylori-related cancer. Cancer Sci. 2006; 97: 1129–38.
45. Kimura R, Nishioka T, Soemantri A, Ishida T. Cis-acting effect of the IL1B C-31T polymorphism on IL-1 beta mRNA expression. Genes Immun. 2004; 5: 572–5.
46. Rad R, Dossumbekova A, Neu B et al. Cytokine gene polymophisms influence mucosal cytokine expression, gastric inflammation and host specific colonisation during Helicobacter pylori infection. Gut 2004; 53: 1082–1089.
47. Yang J, Hu Z, Xu Y et al. Interleukin-1B gene promoter variants are associated with an increased risk of gastric cancer in a Chinese population. Cancer Lett. 2004; 215: 191–8.
48. Palli D, Saieva C, Luzzi I et al. Interleukin-1 gene polymorphisms and gastric cancer risk in a high-risk Italian population. Am. J. Gastroenterol. 2005; 1000: 1941–8.
49. Kamangar F, Cheng C, Abnet C, Rabkin C. Interleukin-1B polymorphisms and gastric cancer risk—a meta analysis. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 1920–8.
50. Persson C, Canedo P, Machado J, El-Omar E, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: a HuGE systemic review and meta-analyses. Am. J. Epidemiol. 2010; 173: 259–70.
51. Ehlers S, Warrelmann M, Hahn H. In research of an animal model for experimental Campylobacter pylori infection: administration of Campylobacter to rodents. Zentralbl Bakteriol Mikrobiol Hyg A. 1988; 268: 341–6.
52. Cantona M, Balish E. Inability of human clinical strains of Helicobacter pylori to colonize the alimentary tract of germfree rodents. Can. J. Microbiol. 1990; 36: 237–41.
53. Lee A, Fox J, Otto G, Murphy J. A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology 1990; 99: 1315–23.
54. Fox J, Sheppard B, Dangler C, Whary M, Ihrig M, Wang T. Germ-line p53 targeted disruption inhibits Helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 pro-inflammatory responses. Cancer Res. 2002; 62: 696–702.
55. Houghton J, Wang T. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 2005; 128: 1567–78.
56. Lee A, CHen M, Coltro N et al. Long term infection of the gastric mucosa with Helicobacter species does induce atrophic gastritis in an animal model of Helicobacter pylori infection. Zentralbl Bakteriol. 1993; 280: 38–50.
57. Stoicov C, Saffari R, Cai X, Hasyagar C, Houghton J. Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma—bacterial and host factors responsible for altered growth signaling. Gene 2004; 341: 1–17.
58. Lee C, Rickman B, Rogers A, Ge Z, Wang T, Fox J. Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res. 2008; 68: 3540–8.
59. Ley C, Mohar A, Guarner J et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol. Biomarkers Prev. 2004; 13: 4–10.
60. Lee A, O'Rourke J, Ungria M, Robertson B, Daskalopoulos G, Dixon M. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997; 112: 1386–97.
61. Wang X, Willen R, Svensson M, Ljungh A, Wadstrom T. Two-year follow-up of Helicobacter pylori infection in C57BL/6 and Balb/cA mice. Acta Pathol. Microbiol. Immunol. Scand. 2003; 111: 512–22.
62. Greenfield L, Jones N. Modulation of autophagy by Helicobacter pylori and its role in gastric carcinogenesis. Trends Microbiol. 2013; 21: 602–12.
63. Maeda S, Yoshida H, Ogura K et al. H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2 and TRAF6 in gastric cancer cells. Gastroenterology 2000; 119: 97–108.
64. Mitsuno Y, Yoshida H, Maeda S et al. Helicobacter pylori induced transactivation of SRE and AP-1 through the ERK signalling pathway in gastric cancer cells. Gut 2001; 49: 18–22.
65. Arnold I, Lee J, Amieva M et al. Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia. Gastroenterology 2011; 140: 199–209.
66. Beckler A, Roche J, Harper J et al. Decreased abundance of trefoil factor 1 transcript in the majority of gastric carcinomas. Cancer 2003; 98: 2184–91.
67. Fujimoto J, Yasui W, Tahara H, Tahara E, Kudo Y, Yokozaki H. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. Cancer Lett. 2000; 149: 125–34.
68. Peterson A, Menheniott T, O'Connor L et al. Helicobacter pylori infection promotes methylation and silencing of Trefoil Fator 2, leading toe gastric tumour development in mice and humans. Gastroenterology 2010; 139: 2005–17.
69. Clyne M, Dillon P, Daly S et al. Helicobacter pylori interacts with the human single domain trefoil protein TFF1. Proc. Natl. Acad. Sci. U. S. A. 2008; 101: 7409–14.
70. Reeves E, Ali T, Leonard P et al. Helicobater pylori lipopolysaccharide interacts with TFF1 in a pH-dependent manner. Gastroenterology 2008; 135: 2043–53.
71. Soutto M, Romero-Gallo J, Krishna3 U et al. Loss of TFF1 promotes Helicobacter pylori-induced β-catenin activation and gastric tumorigenesis. Oncotarget. 2015; 6(20): 17911–22.
72. Wang T, Goldenring J, Dangler C et al. Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection. Gastroenterology 1998; 114: 675–89.
73. Ismail H, Fick P, Zhang J, Lynch R, Berg D. Depletion of neutrophils in IL-10(−/−) mice delays clearance of gastric Helicobacter infection and decreases Th1 immune response to Helicobacter. J. Immunol. 2003; 170: 3782–9.
74. Smythies L, Waites K, Lindsey J, Harris P, Ghiara P, Smith P. Helicobacter pylori-induced inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene deficient mice. J. Immunol. 2000; 165: 1022–9.
75. Fox J, Rogers A, Ihrig M et al. Helicobacter pylori-associated gastric cancer in INS-GAS mice is gender specific. Cancer Res. 2003; 63: 942–50.
76. Toyoda T, Tsukamoto T, Tamamoto M et al. Gene expression analysis of a Helicobacter pylori-infected and high-salt diet-treated mouse gastric tumor model: identification of CD177 as a novel prognostic factor in patients with gastric cancer. BMC Gastroenterol. 2013; 13: 1–11.
77. Lofgren J, Whary M, Ge Z et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 2011; 140: 210–20.
78. Chen D, Stenström B, Zhao C-M, Wadström T. Does Helicobacter pylori infection per se cause gastric cancer or duodenal ulcer? Inadequate evidence in Mongolian gerbils and inbred mice. FEBS Immunol. Med. Biol. 2007; 50: 184–9.
79. Marostica M, Arcari D, Bartchewsky W et al. Effects of a one-week treatment with acid gastric inhibitors on Helicobacter pylori-infected mice. Scand. J. Gastroenterol. 2007; 42: 1404–12.
80. Hahm K, Song Y, Oh E et al. Chemo-prevention of Helicobacter pylori-associated carcinogenesis in a mouse model: is it possible? J. Bichem. Mol. Biol. 2003; 36: 82–94.
81. Zhang S, Lee S, Morrissey R, Aponte-Pieras J, Rogers A, Moss S. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. Cancer Lett. 2014; 355: 106–12.
82. Hilleringmann M, Pansegra W, Doyle M et al. Inhibitors of Helicobacter pylori ATPase Caga block CagA transport and cag virulence. Microbiology 2006; 152: 2919–30.
83. Aristoteli L, O'Rourke J, Danon S et al. Urea, fluorofamide and omeprazole treatments alter Helicobacter colonization in the mouse gastric mucosa. Helicobacter 2006; 11: 460–8.
84. Gavrish E, Shrestha B, Chen C et al In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori. Antimicrob. Agents Chemother. 2014; 58: 3255–60.
85. Shin J, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function and inhibition. Pflugers Arch. 2009; 457: 609–22.
86. Karam S, Forte J. Inhibiting gastric H(+)-K(+)-ATPase activity by omeprazole promotes degeneration and production of parietal cells. Am. J. Physiol. 1994; 266: G7745–58.
87. Li Q, Karam S, Gordon J. Simian virus 40 T antigen-induced amplification of pre-parietal cells in transgenic mice. Effects on other gastric epithelial cell lineages and evidence for a p53-independent apoptotic mechanism that operates in a committed progenitor. J. Biol. Chem. 1995; 270: 15777–88.
88. Spicer Z, Miller M, Angringa A et al. Stomachs of mice lacking the gastric H,K-ATPase alpha-subunit have achlorhydria, abnormal parietal cells and ciliated metaplasia. J. Biol. Chem. 2000; 275: 21555–65.
89. Judd L, Andringa A, Rubio C, Spicer Z, Schull G, Miller M. Gastric achlorhydria in H/K-ATPase-deficient (Atp4a(−/−)) mice causes severe hyperplasia, mucocystic metaplasia and upregulation of growth factors. J. Gastroenterol. Hepatol. 2005; 20: 1266–78.
90. Scarff K, Judd L, Toh B, Gleeson P, Driel IV. Gastric H(+), K(+)-adenosine triphosphatase beta subunit is required for normal function, development, and membrane structure of mouse parietal cells. Gastroenterology 1999; 117: 605–19.
91. Gut M, Vernerova SP, Rohde R et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 2002; 123: 1889–903.
92. Silberg D, Sullivan J, Kang E et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002; 122: 689–96.
93. Mutoh H, Hakamata Y, Sato K et al. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice Biochemical and Biophysical Research. Commun. 2002; 294: 470–9.
94. Silberg D, Furth E, Taylor J, Schuck T, Chiou T, Traber P. CDX1 protein expression in normal, metaplasia, and neoplastic human alimentary tract epithelium. Gastroenterology 1997; 113: 478–86.
95. Mutoh H, Sakurai S, Satoh S et al. Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut 2004; 53: 1416–23.
96. Coffey RJ, Washington MK, Corless CL, Heinrich MC. Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. J. Clin. Invest. 2007; 117: 70–80.
97. Takagi H, Fukusato T, Kawaharada U, Kuboyama S, Merlino G, Tsutsumi Y. Histochemical analysis of hyperplastic stomach of TGF-alpha transgenic mice. Dig. Dis. Sci. 1997; 42: 91–8.
98. Goldenring J, Ray G, Soroka C et al. Overexpression of transforming growth factor-alpha alters differentiation of gastric cell lineages. Dig. Dis. Sci. 1996; 41: 773–84.
99. Dahlhoff M, Gerhard M, Rad R, Linden S, Wolf E, Schneider M. A new mouse model for studying EGFR-dependent gastric polyps. Biochem Biophys Acta. 2012; 1822: 1293–9.
100. Goldenring J, Ray G, Coffey R et al. Reversible drug-induced oxyntic atrophy in rats. Gastroenterology 2000; 118: 1080–93.
101. Nomura S, Yamaguchi H, Ogawa M, Wang T, Lee J, Goldenring J. Alterations in gastric mucosal lineages induced by acute oxyntic atrophy in wild-type and gastrin-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2005; 288: G362–75.
102. Ogawa M, Nomura S, Varro A, Wang T, Goldenring J. Altered metaplastic response of waved-2 EGF receptor mutant mice to acute oxyntic atrophy. Am. J. Physiol. 2006; 290: G793–804.
103. Nam K, Varro A, Coffey R, Goldenring J. Potentiation of oxyntic atrophy-induced gastric metaplasia in amphiregulin-deficient mice. Gastroenterology 2007; 132: 1804–19.
104. Ferrand A, Wang T. Gastrin and cancer. Cancer Lett. 2006; 238: 15–29.
105. Koh T, Goldenring J, Ito S et al. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. Gastroenterology 1997; 113: 1015–25.
106. Wang T, Brand S. Function and regulation of gastrin in transgenic mice: a review. Yale J. Biol. Med. 1992; 65: 705–40.
107. Wang T, Dangler C, Chen D et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000; 118: 36–47.
108. Fox J, Wang T, Rogers A et al. Host and microbial constituents influence Helicobacter pylori-induced cancer in a murine model of hypergastrinemia. Gastroenterology 2003; 124: 1879–90.
109. Ohtani M, Garcia A, Rogers A et al. Protective role of 17 beta-estradiol against the development of Helicobacter pylori-induced gastric cancer in INS-GAS mice. Carcinogenesis 2007; 28: 2597–604.
110. Takaishi S, Tu S, Dubeykovskaya ZA et al. Gastrin is an essential cofactor for Helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice. Am. J. Pathol. 2009; 175: 365–75.
111. Takaishi S, Wang T. Gene expression profiling in a mouse model of Helicobacter-induced gastric cancer. Cancer Sci. 2007; 98: 284–93.
112. Lee C-W, Rickman B, Rogers A et al. Combination of Sulindac and the antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res. 2009; 69: 8166–74.
113. Takaishi S, Cui G, Frederick D et al. Syngergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology 2005; 128: 1695–983.
114. Zavros Y, Rieder G, Ferguson A, Samuelson L, Merchant J. Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. Gastroenterology 2002; 122: 119–33.
115. Friis-Hansen L, Rieneck K, Nilsson H, Wadstrom T, Rehfeld J. Gastric inflammation, metaplasia and tumor development in gastrin-deficient mice. Gastroenterology 2006; 131: 256–8.
116. Schlag P, Bockler P, Peter M. Nitrite and nitrosamines in gastric juice: risk factors for gastric cancer? Scand. J. Gastroenterol. 1982; 17: 145–50.
117. Faller G, Dimmler A, Rau T et al. Evidence for acid-induced loss of Cdx2 expression in duodenal gastric metaplasia. J. Pathol. 2004; 203: 904–8.
118. El-Omar E, Carrington M, Chow W et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398–402.
119. Tu S, Bhagat G, Cui G et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 12: 408–19.
120. Song X, Krelin Y, Dvorkin T et al. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumours of IL-1beta secreting cells. J. Immunol. 2005; 175: 8200–8.
121. Waghray M, Zvros Y, Saqui-Salces M et al. Interleukin-1beta promotes gastric atrophy through suppression of Sonic hedgehog. Gastroenterology 2010; 138: 562–72.
122. Quante M, Tu SP, Tomita H et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19: 257–72.
123. Tatematsu M, Yamamoto M, Iwata H et al. Induction of glandular stomach cancers in C3H mice treated with N-Methyl-N-Nitrosourea in the drinking water. Jpn. J. Cancer Res. 1993; 84: 1258–64.
124. Bromberg J, Wrzeszczynska M, Devgan G et al. stat3 as an oncogene. Cell 1999; 98: 295–303.
125. Bollrath J, Phesse T, Burstin V et al. gp130-mediated stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumourigenesis. Cell 2009; 15: 91–102.
126. Ernst M, Najovska M, Grail D et al. stat3 and stat1 mediate IL-11-dependent and inflammation-associated gastric tumour. J. Clin. Invest. 2008; 118: 1727–8.
127. Putoczki T, Thiem S, Loving A, Busuttil R, Wilson N, Ziegler P. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumourigenesis and can be targeted therapeutically. Cancer Cell 2013; 24: 257–71.
128. Thiem S, Pierce TP, Palmieri M et al. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J. Clin. Invest. 2013; 123: 767–80.
129. Judd L, Alderman B, Howlett M, Shilkes A, Dow C, Moverly J. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology 2004; 126: 197–207.
130. Jenkins B, Grail D, Nheu T, Nakdovska M, Wang B, Waring P. Hyperactivation of stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signalling. Nat. Med. 2005; 11: 845–52.
131. Tye H, Kennedy C, Najdovska M et al. stat3-driven upregulation of TLR2 promotes gastric tumourigenesis independent of tumor inflammation. Cancer Cell 2012; 22: 466–78.
132. Uno K, Kato K, Atsumi T et al. Toll-like receptor (TLR)2 induced through TLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS2 induction in gastric epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 293: G1004–G12.
133. Tahara T, Arisawa T, Wang F et al. Toll-like receptor 2 −196 to 174 del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci. 2007; 98: 1790–4.
134. Hold G, Rabkin C, Chow W et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric cancer and its precursors. Gastroenterology 2007; 132: 905–12.
135. Kennedy C, Najdovska M, Tye H et al. Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis. Oncogene 2014; 33: 2540–6.
136. Mistrya P, Lairda MHW, Schwarza RS et al. Inhibition of TLR2 signaling by small molecule inhibitors targeting a pocket within the TLR2 TIR domain. Proc. Natl. Acad. Sci. U. S. A. 2015; 112: 5455–60.
137. Zhou S, Cerny A, Bowen G et al. Discovery of a novel TLR2 signaling inhibitor with anti-viral activity. Antiviral Res. 2010; 87: 295–306.
138. Heinrich P, Behrmann I, Haan S, Hermanns H, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003; 374: 1–20.
139. Stuart E, Buchert M, Putoczki T et al. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice. Mol. Cancer Ther. 2014; 13: 468–74.
140. Judd L, Menheniott T, Ling H et al. Inhibition of the JAK2/stat3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS One 2014; 9: 1–9.
141. Sonbol M, Firwana B, Zarzour A, Morad M, Rana V, Tiu R. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther. Adv. Hematol. 2013; 4: 15–35.
142. Jancik S, Drabek J, Radzioch D, Hajduch M. Clinical relevance of KRAS in human cancers. J. Biomed. Biotechnol. 2010; 2010: 1–13.
143. Okumura T, Ericksen R, Taishi S et al. K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasia. Cancer Res. 2010; 70: 8435–45.
144. Ray K, Bell K, Yan J et al. Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PLoS One 2011; 6: e16786.
145. Matkar S, Durham A, Brice A, Wang T, Rustgi A, Hua X. Systemic activation of K-ras rapidly induces gastric hyperplasia and metaplasia in mice. Am. J. Cancer Res. 2011; 1: 432–45.
146. Bossenmeyer-Pourie C, Kannan R, Ribieras S, Wendling C, Stoll I, Thim L. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J. Cell Biol. 2002; 157: 761–70.
147. Tomasetto S, Masson R, Linares J, Wendling C, Lefebvre O, Chenard M. ps2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins. Gastroenterology 2000; 118: 70–80.
148. Rio M, Chenard M, Wolf C, Marcellin L, TOmasetto C, Lathe R. Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract. Gastroenterology 1991; 100: 375–9.
149. Kjellev S. The trefoil factor family—small peptides with multiple functionalities. Cell. Mol. Life Sci. 2009; 66: 1350–69.
150. Playford R, Marchbank T, Goddlad R, Chinery R, Poulsom R, Hanby A. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 2137–42.
151. Lefebvre O, Chenard M, Masson R et al. Gastric mucosa abnormalities and tumourigenesis in mice lacking the pS2 trefoil protein. Science 1996; 274: 259–62.
152. Soutto M, Belkhiri A, Piazuelo M et al. Loss of TFF is associated with activation of NF-kB-mediated inflammation and gastric neoplasia in mice and humans. J. Clin. Invest. 2011; 121: 1753–67.
153. Saukkonen K, Tomasetto C, Narko K, Rio M, Ristimaki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res. 2003; 63: 3032–6.
154. Mrena J, Wiksten J, Thiel A et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin. Cancer Res. 2005; 11: 7362–8.
155. Rees B, Saukkonen K, Ristimaki A et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J. Pathol. 2002; 196: 171–9.
156. Saukkonen K, Nieminen O, Rees V et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin. Cancer Res. 2001; 7: 1923–31.
157. Thiel A, Narko K, Heinonen M et al. Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. Int. J. Cancer 2012; 131: 1032–41.
158. Sakamoto H, Yoshimura K, Saeki N et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 2008; 40: 730–40.
159. Abnet C, Freedman N, Hu N et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat. Genet. 2010; 42: 764–7.
160. Thiem S, Eissmann MF, Elzer J, Jonas A et al. Stomach-specific activation of oncogenic KRAS and STAT3-dependent inflammation cooperatively promote gastric tumorigenesis in a preclinical model. Cancer Res. 2016; [Epub ahead of print].
161. Holmlund C, Nilsson J, Guo D et al. Characterization and tissue-specific expression of human LRIG2. Gene 2004; 12: 35–43.
162. Nam K, Lee H, Sousa J et al. Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology 2010; 139: 2028–37.
163. Quante M, Marrache F, Goldenring J, Wang T. TFF2 mRNA transcript expression markers a gland progenitor cell of the gastric oxyntic mucosa. Gastroenterology 2010; 139: 2018–27.e2.
164. Hahm K, Lee K, Kim Y et al. Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment. Pharmacol. Ther. 2002; 16: 115–27.
165. Tatematsu M, Ogawa K, Hoshiya T, Shichino Y, Kato T, Imaida K. Induction of adenocarcinomas in the glandular stomach of BALB/c mice treated with N-methyl-N-nitrosourea. Jpn. J. Cancer Res. 1992; 83: 915–8.
166. Nakamura Y, Sakagami T, Yamamoto N et al. Helicobacter pylori does not promote N-Methyl-N-nitrosourea-induced gastric carcinogenesis in SPF C57BL/6 mice. Jpn. J. Cancer Res. 2002; 93: 111–6.
167. Han S, Kim Y, Koo H et al. Helicobater pylori infection promotes gastric carcinogenesis in a mice model. J. Gastroenterol. Hepatol. 2002; 17: 253–61.
168. Nagata A, Ito M, Iwata N et al. G protein-coupled cholecystokinin-B/gastric receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 11825–30.
169. Nomura S, Settle S, Leys C et al. Evidence for repatterning of the gastric fundic epithelial associated with Menetrier's disease and TGFalpha overexpression. Gastroenterology 2005; 128: 1292–305.
170. Franic T, Judd L, Robinson D et al. Regulation of gastric epithelial cell development revleaed in H(+)/K(+)-ATPase beta-subunit and gastrin-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2001; 281: G1502–11.
171. Syu S, El-aatari M, Eaton K et al. Transgenic expression of Interferon-y in mouse stomach leads to inflammation, metaplasia and dysplasia. Am. J. Pathol. 2012; 181: 2114–25.
172. Xiao C, Ogle S, Schumacher M et al. Loss of parietal cell expression of Sonic hedgehog induces hypergastrinemia and hyperproliferation of surface mucous cells. Gastroenterology 2010; 138: 550–61.
173. Nam K, Lee H, Sousa J et al. Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology 2010; 129: 2028–37.
174. Schultheis P, Clarke L, Meneton P et al. Targeted disruption of the murine Na/H+ exchanger isoform 2 gene causes reduced viability of gastric parietal cells and loss of net acid secretion. J. Clin. Invest. 1998; 101: 1243–53.
175. Kanda N, Seno H, Kawada M et al. Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice. Am. J. Physiol. 2006; 290: G519–G27.
176. Andersson P, McGuire J, Rubio C et al. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 9990–5.
177. Thompson J, Epting T, Schwarzkopf G et al. A transgenic mouse line that develops early-onset invasive gastric carcinoma provides a model for carcinoembryonic antigen-targeted tumor therapy. Int. J. Cancer 2000; 86: 863–9.
178. Shimada S, Mimata A, Sekine M et al. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut 2012; 61: 344–53.
179. Mutoh H, Sakurai S, Satoh K et al. Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice. Cancer Res. 2004; 64: 7740–7.
180. Hahn J, Falck V, Jirik F. Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice. J. Clin. Invest. 2011; 121: 4030–42.
181. Barker N, Huch M, Kujala P et al. Lgr5+ve stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 2010; 6: 25–36.
182. Koike K, Hinrichs S, Isselbacher K, Jay G. Transgenic mouse model for human gastric carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 5615–9.
183. Tsuzuki T, Egashira A, Igarashi H et al. Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase. Proc. Natl. Acad. Sci. U. S. A. 2001; 25: 11456–61.
184. Nam KT, O'Neal R, Lee YS, Lee YC, Coffey RJ, Goldenring JR. Gastric tumor development in Smad3-deficient mice initiates from forestomach/glandular transition zone along the lesser curvature. Lab. Invest. 2012; 92: 883–95.
185. Takaku K, Miyoshi H, Matsunaga A, Oshima M, Sasaki N, Taketo M. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res. 1999; 59: 6113–7.
186. Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo M, Oshima M. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology 2006; 131: 1086–95.